Man­u­fac­tur­ing roundup: Touch­light nets $2M grant from the Gates Foun­da­tion; Ex­per­ic clos­es $14M Se­ries B

The man­u­fac­tur­er of the “Dog­gy­bone DNA” syn­thet­ic vec­tor has net­ted deals with big names, the lat­est of which is a grant from the Bill & Melin­da Gates Foun­da­tion to help fur­ther Touch­light’s “pre­clin­i­cal de­vel­op­ment” of its vac­cine plat­form.

The vac­cine pro­gram aims to build on ev­i­dence that the syn­thet­ic DNA the com­pa­ny pro­duces can pro­duce strong an­ti­bod­ies and durable T cell re­spons­es fol­low­ing vac­cine ad­min­is­tra­tion.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.